M. Mancini; V. Corradi; S. Petta; G. Martinelli; E. Barbieri; M.A. Santucci, mTOR inhibitor RAD001 (Everloimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-Abl protein, «LEUKEMIA RESEARCH», 2010, 34, pp. 641 - 648 [articolo]
M. Mancini; S. Petta; G. Martinelli; E. Barbieri; M.A. Santucci, RAD001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia, «JOURNAL OF CELLULAR BIOCHEMISTRY», 2010, 109, pp. 320 - 328 [articolo]
Mancini M.; Petta S.; Iacobucci I.; Salvestrini V. ; Barbieri E.; Santucci M. A., Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells., «CELLULAR SIGNALLING», 2010, 22 (8), pp. 1247 - 1253 [articolo]
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M., C6-Unsubstituted Pyrazolo[3,4-d]pyrimidines Are Dual Src/Abl Inhibitors Effective against Imatinib Mesylate Resistant Chronic Myeloid Leukemia Cell Lines., «CHEMMEDCHEM», 2009, 4(1), pp. 118 - 126 [articolo]
Radi M; Crespan E; Botta G; Falchi F; Maga G; Manetti F; Corradi V; Mancini M; Santucci MA; Schenone S; Botta M., Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents., «BIOORGANIC & MEDICINAL CHEMISTRY LETTERS», 2008, 18, pp. 1207 - 1211 [articolo]
Corradi V.; Mancini M.; Corrado P.; Barbieri E.; Santucci M.A.; Schenone S.; Botta M., A new class of dual SRC/ABL kinase inhibitors for the treatment of imatinib-resistant chronic myeloid leukemias, in: Haematologica- The Hematology Journal
41th Congress of the Italian Society of Hematology-Abstract book, PAVIA, s.n, 2007, s3, pp. 173 - 173 (atti di: 41th Congress of the Italian Society of Hematology, Bologna, 14-17 Ottobre 2007) [atti di convegno-abstract]
Brusa G; Zuffa E; Hattinger CM; Serra M; Remondini D; Castellani G; Righi S; Campidelli C; Pileri S; Zinzani PL; Gabriele A; Mancini M; Corrado P; Barbieri E; Santucci MA., Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma., «ONCOLOGY REPORTS», 2007, 18(6), pp. 1427 - 1434 [articolo]
Brusa G.; Zuffa E.; Remondini D.; Castellani G.; Serra M.; Hattinger C.M.; Morandi L.; Zinzani P.L.; Mancini M.; Corrado P.; Barbieri E.; Santucci M.A., Genomic instability in the development of non-Hodgkin lymphomas secondary to Hodgkin lymphoma, in: 41th Congress of the Italian Society of Hematology- Abstract Book, PAVIA, s.n, 2007, s3, pp. 48 - 48 (atti di: 41th Congress of the Italian Society of Hematology, Bologna, 14-17 Ottobre 2007) [atti di convegno-abstract]
Mancini M; Brusa G; Zuffa E; Corrado P; Martinelli G; Grafone T; Barbieri E; Santucci MA, Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606, «LEUKEMIA RESEARCH», 2007, 31(7), pp. 979 - 987 [articolo]
Corrado P.; Brusa G.; Mancini M.; Zuffa E.; Corradi V.; Martinelli G.; Barbieri E.; Santucci M.A., Post-translational modifications of FOXO3a transcription factor associated with the constitutive tyrosine kinase activity of p210 BCR-ABL protein. Implications for new targeted therapies, in: Haematologica-The Hematology Journal
41th Congress of the Italian Society of Hematology- Abstract Book, PAVIA, s.n, 2007, s3, pp. 180 - 180 (atti di: 41th Congress of the Italian Society of Hematology, Bologna, 14-17 Ottobre 2007) [atti di convegno-abstract]
Mancini M.; Zuffa E.; Corrado P.; Pagnotta E.; Brusa G.; Corradi V.; martinelli G.; Barbieri E.; Santucci M.A., The m-TOR inhibitor everolimus complements pro-apoptotic and anti-proliferative effects of imatinib on chronic myeloid leukemia progenitors by promoting the nuclear import of normal c-Abl protein, in: 41th congress of the Italian Society of Hematology-Abtrsact Book, PAVIA, s.n, 2007, s3, pp. 44 - 44 (atti di: 41th congress of the Italian Society of Hematology, Bologna, 14-17 OPttobre 2007) [atti di convegno-abstract]
Mancini M.; Zuffa E.; Corrado P.; Brusa G.; Petta S.; Pagnotta E.; Santucci M.A., Apoptotic death of Bcr-Abl-expressing myeloid progenitors in response to the m-Tor inhibitor RAD001 (Everolimus) is promoted by the nuclear import of c-Abl, in: Blood, WASHINGTON D.C., s.n, 2006, 108, pp. 604A - 604A (atti di: America Society of hematology, Orlando (FL), December 5-8, 2006) [atti di convegno-abstract]
Brusa G; Zuffa E; Mancini M; Benvenuti M; Calonghi N; Barbieri E; Santucci MA., P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors, «BRITISH JOURNAL OF HAEMATOLOGY», 2006, 132 (3), pp. 359 - 369 [articolo]
Brusa G.; Mancini M.; Zuffa E.; Santucci M.A., HDAC1 (histone deacetylase1) involvement in Chronic Myeloid Leukemia, in: ASSOCIAZIONE NAZIONALE BIOTECNOLOGI ITALIANI, Biofutura, BOLOGNA, s.n, 2005, pp. 25 - 26 (atti di: Biofutura - Primo Congresso Nazionale dei Biotecnologi Italiani, Bologna, 8-10 Aprile 2005) [Contributo in Atti di convegno]
M. Mancini; G. Brusa; E. Zuffa; T. Graffone; F. Pennisi; N. Calonghi; L. Masotti; M. A. Santucci, NEW STRATEGIES IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA. COMBINED USE OF SRC AND TYROSINE KINASE INHIBITORS CIRCUMVENTS THE DEVELOPMENT OF DRUG-RESISTANCE, in: CIB, CNB8, SIENA, Tipografia Senese, 2005, 8, pp. 48 - 48 [Contributo in Atti di convegno]
